Rontalizumab Therapy Found to Offer a Clinical Benefit to Particular Group of Lupus Patients
A new study recently published in the journal Annals of the Rheumatic Diseases revealed the results of a Phase II trial assessing the use of the investigational therapeutic agent rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (SLE). The study was conducted by researchers at the…